Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

BACKGROUND: The potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect of empagliflozin on metabolic syndrome rats with prediabetes. METHODS: SHR/NDmcr-cp(+/+) rats (SHRcp), a model of metabolic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusaka, Hiroaki, Koibuchi, Nobutaka, Hasegawa, Yu, Ogawa, Hisao, Kim-Mitsuyama, Shokei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106779/
https://www.ncbi.nlm.nih.gov/pubmed/27835975
http://dx.doi.org/10.1186/s12933-016-0473-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106779/
https://www.ncbi.nlm.nih.gov/pubmed/27835975
http://dx.doi.org/10.1186/s12933-016-0473-7

Ejemplares similares